Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2

Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emergency use authorization (EUA) for several SARS-CoV-2 targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Yun, Zhang, Qi, Cheng, Lin, Ge, Jiwan, Wang, Ruoke, Fang, Mengqi, Mucker, Eric M., Chen, Peng, Ma, Ji, Zhang, Rui, Li, Chunming, Hammond, Holly, Baracco, Lauren, Holbrook, Michael, Frieman, Matthew, Zhang, Zheng, Wang, Xinquan, Hooper, Jay W., Zhang, Linqi, Zhu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518701/
https://www.ncbi.nlm.nih.gov/pubmed/36189212
http://dx.doi.org/10.3389/fimmu.2022.980435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518701/
https://www.ncbi.nlm.nih.gov/pubmed/36189212
http://dx.doi.org/10.3389/fimmu.2022.980435

Ejemplares similares